evipedia.ai
← Back

L-Threonine for Health & Longevity

Evidence Review created on 09/10/2026 using AI4L / Opus 5

Also known as: Threonine, Thr, 2-amino-3-hydroxybutanoic acid, L-2-amino-3-hydroxybutyric acid

Motivation

Threonine is one of the nine amino acids the human body cannot build for itself and must take in from food. It is concentrated in the protective mucus lining of the gut, in connective tissue, and in the proteins of muscle and skin. Sold cheaply as a single-ingredient powder, it has drawn interest from people who prefer to target one building block rather than simply eat more protein.

Its history is unusual. Threonine was the last of the essential amino acids to be identified, in the early 1930s, and for decades its largest commercial use was as an additive in livestock feed. In the late 1980s neurologists began giving it in gram-sized daily doses to people with stiff, overactive muscles caused by nerve injury, on the reasoning that it would raise a calming chemical signal in the spinal cord. Laboratory work in worms has since linked it to slower biological aging.

This review examines what supplemental threonine does in humans: how much the body needs, what controlled trials have measured, how much can be taken without harm, and where the evidence ends and speculation begins.

Benefits - Risks - Protocol - Conclusion

High-level sources that treat L-threonine, or essential amino acid supplementation as a category, in enough depth to frame the evidence that follows.

No relevant content was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser or Lifespan.io. Searches of each platform and of the open web returned only passing mentions of threonine inside broader protein and amino acid material, none of which examines it.

Grokipedia

Threonine

A structured overview of threonine chemistry, dietary sources, metabolism and the pseudogene status of the human dehydrogenase, sourced largely from primary biochemistry literature rather than consumer material.

Examine

No Examine article exists for L-threonine; a direct site search returns no results for the term.

ConsumerLab

No ConsumerLab article or product review exists for L-threonine; a direct site search returns only unrelated reviews in which the term appears inside the full report text.

Systematic Reviews

PubMed systematic reviews and meta-analyses bearing on L-threonine — covering its efficacy in neuromuscular disease, its dietary requirement, and the outcomes associated with intake — none of which evaluates the safety of supplemental L-threonine itself.

Mechanism of Action

Threonine is an indispensable amino acid: humans have no synthetic route for it. Its first destination is protein synthesis. It is unusually concentrated in mucins, the gel-forming proteins of intestinal mucus, whose repeating regions run roughly one-quarter to one-third threonine, so much of the dietary supply is consumed by the gut wall before reaching the circulation.

Human breakdown is unusual. Most mammals degrade threonine toward glycine via threonine dehydrogenase; in humans that gene is a pseudogene, transcribed but yielding a non-functional protein, so the glycine route is largely closed (Edgar, 2002). Catabolism instead runs through threonine dehydratase to 2-oxobutyrate and propionyl-CoA, feeding the citric acid cycle that generates cellular energy, which is why plasma 2-aminobutyrate rises alongside threonine after dosing (Matsumoto et al., 2025).

Pharmacologically it behaves as a nutrient, not a drug: no receptor selectivity, absorption by neutral amino acid transporters, distribution into the free amino acid pool with highest concentrations in gut mucosa, muscle and liver, clearance by liver and gut enzymes rather than cytochrome P450 (CYP) drug-metabolising enzymes, and no published elimination half-life.

Two accounts of its aging effects compete. One holds threonine itself protective, activating the stress regulators DAF-16 and HSF-1 (proteins that switch on cellular defence genes) and suppressing ferroptosis, an iron-driven form of cell death (Kim et al., 2022). The other holds the reverse: blocking threonine breakdown extends life through small hormetic doses (brief mild stress that triggers repair) of methylglyoxal, a reactive by-product (Ravichandran et al., 2018).

Historical Context & Evolution

Threonine was the last essential amino acid to be characterised. William Cummings Rose isolated it in 1935 while completing the list of amino acids required for growth, and the nitrogen-balance experiments he ran on human volunteers in the 1950s produced the first requirement figure. Its original practical use was agricultural rather than therapeutic: threonine is the second or third limiting amino acid in cereal-based pig and poultry diets, and industrial fermentation using Escherichia coli and Corynebacterium glutamicum made bulk crystalline L-threonine cheap enough to add routinely to feed (Tang et al., 2021).

Interest in human dosing came from neurology. Rodent work had shown that oral threonine raised spinal cord glycine, a calming neurotransmitter, so investigators reasoned it might damp the excess muscle tone of upper motor neuron injury, a state called spasticity. Trials followed between 1989 and 1993 in familial spastic paraparesis (an inherited stiffening and weakness of the legs), spinal spasticity, and amyotrophic lateral sclerosis (ALS). The spasticity trials found small but statistically significant reductions in muscle tone; the ALS trials found no effect on survival or function. The spasticity work also found that spinal fluid glycine did not rise, undercutting the mechanism the trials were designed to test (Growdon et al., 1991).

The programme was not so much refuted as abandoned once riluzole and botulinum toxin offered stronger options; the controlled trials were never repeated at higher doses or longer durations.

Expected Benefits

High 🟩 🟩 🟩

Reduction of Spasticity in Upper Motor Neuron Disorders

Supplemental L-threonine modestly lowers muscle tone in people whose stiffness arises from damage to the descending motor pathways. Two double-blind crossover trials tested it: 18 patients with familial spastic paraparesis at 4.5–6 g daily (Growdon et al., 1991) and 33 patients with spinal spasticity at 6 g daily scored on the Ashworth Scale, a validated rating of muscle tone (Lee & Patterson, 1993). Both favoured threonine. The Growdon investigators judged the change real but not clinically valuable, and spinal fluid glycine did not rise.

Magnitude: In the 33-patient spinal spasticity trial, sequential analysis stopped in favour of L-threonine at 6 g daily using a 10% or greater fall in Ashworth score as the response threshold; in the 18-patient paraparesis trial, severity ratings fell against placebo at 4.5–6 g daily (p < 0.02, meaning under a 2% chance the difference arose from chance alone).

Medium 🟩 🟩

No benefit reaches Medium: apart from the two spasticity trials, the remaining human evidence consists of stable-isotope tracer studies that measure amino acid oxidation rather than a clinical endpoint or a validated clinical surrogate, and the gut-barrier findings come from livestock and rodent models.

Low 🟩

Meeting the Threonine Requirement on Low-Protein or Plant-Predominant Diets

Supplemental threonine closes a dietary shortfall when intake is low. The target itself is disputed: tracer studies in healthy adults place the mean requirement between roughly 10 and 19 mg per kilogram daily, far above the older 7 mg estimate (Wilson et al., 2000; Szwiega et al., 2023).

Magnitude: Mean requirement 19.0 mg per kilogram daily with an upper safe intake of 26.2 mg per kilogram daily by tracer oxidation (Wilson et al., 2000) — about 1.3 g and 1.8 g daily for a 70 kg adult. A later protocol in the same population returned 10.5–12.1 mg per kilogram daily, and a 24-hour balance study in Indian men returned 15 mg per kilogram daily (Kurpad et al., 2002).

Speculative 🟨

Intestinal Mucin Synthesis and Barrier Integrity

Threonine dominates the amino acid content of mucins, and supplementation raises mucus output in piglets and poultry (Mao et al., 2011). Basis is animal only; no human outcome data exist.

Immune Support via Antibody and Mucosal Protein Synthesis

Antibodies and gut immune proteins are threonine-rich, and supplementation modulates intestinal immune signalling in pigs and poultry (Tang et al., 2021). Basis is animal and compositional only; no human outcome data.

Healthspan Extension via Ferroptosis Resistance ⚠️ Conflicted

In roundworms, threonine extended healthspan by blocking ferroptosis (Kim et al., 2022); another group found the opposite manipulation, blocking threonine breakdown, also extends life (Ravichandran et al., 2018). Net reading: unresolved, untested in humans.

Glycinergic Sedation and Sleep Support

Threonine has been given specifically to raise glycine. The one trial measuring it found no rise in blood or spinal fluid (Growdon et al., 1991), so any sedative or sleep benefit rests on mechanism alone.

Connective Tissue and Skin Protein Support

Threonine appears in collagen and elastin, and marketing extrapolates from this to skin or joint benefit. No controlled human trial has tested it on skin, collagen turnover, or wound healing; the basis is compositional only.

Prevention of Liver Fat Accumulation

Threonine is marketed as keeping fat from building up in the liver. Supplementation lowered liver lipid, triglyceride and cholesterol in ducks fed reduced-protein diets (Jiang et al., 2017). Basis is poultry only; no human data.

Benefit-Modifying Factors

  • Threonine dehydrogenase (TDH) gene status: Every human carries a non-functional TDH gene, the enzyme that would convert threonine to glycine, so that route is closed for all; no known variant makes threonine supplementation more or less useful (Edgar, 2002).

  • Propionate pathway gene variants: Carriers of PCCA, PCCB or MUT variants (genes for the enzymes that clear the propionyl fragment) route threonine less efficiently; people with one affected copy are usually symptom-free but have less headroom for a large propionate load.

  • Baseline plasma threonine and intake: Benefit scales with deficit: fasting plasma threonine low in its reference range, or protein intake below 0.8 g per kilogram daily, marks room to gain; replete individuals show no further response (Wilson et al., 2000).

  • Sex: Every controlled trial of supplemental threonine in healthy adults enrolled men only, including the 2025 dose-ranging safety study (Matsumoto et al., 2025); the spasticity trials included both sexes but did not analyse by sex. No sex-specific benefit difference can be stated.

  • Pre-existing conditions: Inflammatory bowel disease raises gut threonine demand: intestinal inflammation increases mucosal threonine uptake in animal models, and a dedicated requirement trial in Crohn’s disease is underway (NCT04740541). Malabsorption similarly widens the gap.

  • Age: Mucus barrier function declines with age in animals, which is the rationale for an ongoing requirement trial in adults over 60 (NCT06225648). Until it reports, requirement figures for people over 60 are extrapolated from young men.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse effect of supplemental L-threonine has been documented as a clinical event or as a validated clinical surrogate in more than one controlled human trial — only a single dose-ranging safety trial exists, and the older neurological trials recorded adverse events without arm-level rates.

Medium 🟥 🟥

Transient Rises in Liver and Muscle Enzymes at Gram Doses

The only dose-ranging safety trial gave healthy men 0, 3, 6, 9 and 12 g daily for four weeks in a crossover design and found a minor, non-specific rise in plasma aspartate aminotransferase (AST, a liver and muscle enzyme) and creatine kinase (CK, released when muscle cells are stressed) at 9 g daily, but not at 12 g (Matsumoto et al., 2025). The absence of a dose gradient argues against a true threonine effect, though it has not been re-tested. All participants were men aged around 43.

Magnitude: Reported as a minor, non-specific elevation of aspartate aminotransferase and creatine kinase at 9 g daily only, with no elevation at 12 g; the trial gives the direction without effect-size figures and set the no-observed-adverse-effect level (NOAEL, the highest dose producing no detectable harm) at 12 g daily.

Low 🟥

Added Propiogenic Load in Inherited Disorders of Propionate Metabolism

Threonine is one of four amino acids whose breakdown yields propionyl-CoA. In propionic and methylmalonic acidemia, inherited faults in clearing that fragment, dietary management restricts exactly these amino acids, so supplemental threonine is a direct substrate load (Saleemani et al., 2021).

Magnitude: Direction only: threonine intake raises propionate precursor supply, and the effect holds specifically in people with propionyl-CoA carboxylase or methylmalonyl-CoA mutase deficiency, in whom clinical dietary protocols restrict valine, isoleucine, methionine and threonine together. The literature reports no outcome figure for supplemental threonine alone in these disorders.

Higher Blood Pressure Associated with Higher Hydroxyl Amino Acid Intake

A meta-analysis of 16 observational studies found that people in the highest intake quartile of hydroxyl-group (“alcoholic”) amino acids, the class comprising threonine and serine, had higher odds of high blood pressure (Izadi et al., 2025). Dietary intake is not supplementation, and confounding by total protein intake is unresolved.

Magnitude: Direction only for the hydroxyl class: odds of hypertension rose across ascending intake quartiles. The meta-analysis reports no separate outcome figure for hydroxyl amino acids; its pooled odds ratio (OR, the multiplier on the odds of an outcome) of 1.66, 95% confidence interval (CI, the range within which the true value most likely falls) 1.31–2.11 for the highest versus lowest quartile combines the branched-chain, aromatic and hydroxyl amino acid groups across 16 studies and 57,913 participants (Izadi et al., 2025).

Nonspecific Gastrointestinal and Systemic Symptoms

Gram doses of a single crystalline amino acid can provoke nausea, loose stools, headache or rash. Controlled trials describe side effects as minimal; in the dose-ranging trial mild-to-moderate events occurred at random across placebo and threonine arms and resolved during continued dosing (Matsumoto et al., 2025).

Magnitude: Not quantified in available studies. The dose-ranging trial recorded adverse events but reported only that mild-to-moderate symptoms occurred at random and resolved without stopping supplementation, so no arm-specific incidence rate exists.

Speculative 🟨

Dicarbonyl Stress from Threonine Catabolism

Threonine breakdown can generate methylglyoxal, a reactive compound implicated in diabetic tissue damage. Roundworm work shows the dose-response is non-linear: low amounts extend life, high amounts are toxic (Ravichandran et al., 2018). No human data.

Support of Tumour Protein Synthesis

Threonine accumulates in glioblastoma (a brain cancer) stem cells and feeds a transfer RNA modification that favours cell-division genes; dietary threonine restriction slowed tumour growth in mice (Wu et al., 2024). No human data.

Delayed Recovery in Active Colitis

In mice with chemically induced colitis, threonine given at disease onset delayed recovery and impaired mucus production; the same dose given after inflammation was established did not (Gaifem et al., 2018). Isolated animal report.

Risk-Modifying Factors

  • Propionyl-CoA carboxylase and methylmalonyl-CoA mutase variants: Two faulty copies of PCCA, PCCB or MUT make threonine a hazard rather than a nutrient, restricted alongside valine, isoleucine and methionine; carriers of one copy have narrower headroom (Saleemani et al., 2021).

  • Baseline liver and muscle enzymes: People starting with aspartate aminotransferase or creatine kinase already above range cannot distinguish a supplement effect from their baseline; the single dose-ranging trial excluded such participants, so its safety margin does not extend to them.

  • Sex: The 12 g daily no-observed-adverse-effect level was established in men only, at an average weight typical of Japanese adult males. Women, and anyone substantially lighter, sit at a higher dose per kilogram at the same gram intake.

  • Pre-existing conditions: Active colitis is the clearest caution, given the animal finding that threonine at disease onset delayed recovery. Advanced liver or kidney disease impairs amino acid handling and shifts the risk balance; neither has been studied with threonine.

  • Age: Vitamin B12 status falls with age and with declining stomach acid production, and the propionate route that clears threonine depends on B12. Older adults with marginal B12 carry a larger metabolic burden from gram doses.

Key Interactions & Contraindications

Prescription medications

  • Antispasticity medications (baclofen, tizanidine, dantrolene): Caution — additive tone reduction could produce excess weakness or sedation. The controlled trials added threonine on top of existing antispastics without dose changes; holding the drug dose steady and reassessing muscle tone after two weeks is the mitigation.

  • Levodopa-containing Parkinson’s medications (levodopa/carbidopa): Monitor — protein and free amino acids can compete with levodopa for intestinal and blood-brain transport, blunting the dose. Threonine competes less than branched-chain amino acids, but separating intake by at least one hour removes the question.

  • Vitamin B12-depleting drugs (metformin, proton pump inhibitors such as omeprazole, nitrous oxide): Monitor — threonine is cleared through a B12-dependent step, so depleted B12 status narrows that route and raises methylmalonic acid. Checking B12 and methylmalonic acid before sustained gram dosing is the mitigation.

Over-the-counter medications

  • Antacids and acid reducers (omeprazole, famotidine, calcium carbonate): Monitor — reduced stomach acid impairs vitamin B12 release from food, indirectly narrowing the pathway that clears threonine. The consequence is a rising methylmalonic acid level rather than an acute event; annual B12 rechecks cover it.

  • Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, aspirin): Caution — these thin the intestinal mucus layer that threonine supplies. No interaction study exists; the practical consequence is that any gut-barrier rationale for threonine is undercut by continued heavy use.

Supplement interactions

  • Glycine and serine: Caution — all three compete for the same neutral amino acid transporters, so stacking gram doses can blunt absorption of each. Separating glycine and threonine by two hours where both exceed 3 g is the standard mitigation.

  • Vitamin B12, biotin and vitamin B5 (pantothenic acid): Additive and supportive — these are cofactors for the propionyl-CoA route that disposes of threonine. Adequacy of all three is the mitigating action for a sustained gram-level threonine load; no upper-dose caution applies.

  • Additive muscle-relaxing supplements (magnesium glycinate, high-dose glycine, valerian, cannabidiol): Caution — each independently lowers muscle tone or sedates, so combining them with threonine for stiffness can produce more weakness or drowsiness than intended. Adding one agent at a time is the mitigation.

  • Balanced essential amino acid and whey formulas: Monitor — these already supply roughly 0.5–1.5 g of threonine per serving, so adding a single-amino-acid powder on top double-counts. Subtracting the formula’s threonine content before setting a separate dose is the mitigation.

Other intervention interactions

  • Low-protein and protein-restricted diets: Monitor — a therapeutic protein restriction for chronic kidney disease or an inherited metabolic disorder is undone by adding a free amino acid. Any threonine dose is counted inside the prescribed protein allowance, not on top of it.

  • Ketogenic and very-low-carbohydrate diets: Monitor — threonine is glucogenic (its carbon skeleton can be converted to glucose), so gram doses contribute glucose-forming substrate. The consequence is a modest rise in blood glucose or a fall in ketones in people tracking either closely.

Populations who should avoid L-Threonine:

  • Propionic acidemia and methylmalonic acidemia — absolute contraindication; threonine is one of the four restricted precursor amino acids
  • Maple syrup urine disease and other disorders managed on a prescribed amino acid formula — absolute contraindication outside metabolic team supervision
  • Chronic kidney disease stage 4 or 5 (estimated glomerular filtration rate below 30 mL/min/1.73 m²) on a prescribed protein restriction — avoid unless the dose is counted within the allowance
  • Decompensated cirrhosis (Child-Pugh Class C, the most severe grade of liver failure) — avoid; amino acid handling is unreliable
  • Active flare of ulcerative colitis or Crohn’s disease — avoid initiation during the flare, based on the animal finding of delayed recovery
  • Pregnancy and lactation — avoid supplemental gram doses; no human safety data exist above dietary intake
  • Children and adolescents under 18 — avoid; requirement and safety data in this age group come from tracer studies, not supplementation trials

Risk Mitigation Strategies

  • Low starting dose with slow titration: protocols begin at 1–2 g daily for two weeks, rising by 1–2 g fortnightly; this limits the nausea and loose stools gram doses of a crystalline amino acid provoke.

  • Chronic ceiling of 6 g daily: the only dose-ranging trial ran four weeks and set the no-observed-adverse-effect level at 12 g in men; a long-term ceiling of half that leaves margin against the unexplained enzyme rise seen at 9 g.

  • Baseline and eight-week enzyme panel: measuring aspartate aminotransferase, alanine aminotransferase and creatine kinase before starting and eight weeks after reaching target dose detects the enzyme elevation reported at 9 g daily.

  • Vitamin B12 sufficiency before dosing above 3 g: serum B12 with methylmalonic acid identifies a constrained propionate route, the same pathway that disposes of supplemental threonine, before a gram-level load is added.

  • Counting threonine inside total protein intake: subtracting the dose from the daily protein target rather than adding it on top prevents an unbalanced amino acid pattern and protects prescribed restrictions in kidney and metabolic disease.

  • Deferral during an active bowel flare: withholding threonine while ulcerative colitis or Crohn’s disease is flaring reflects the mouse finding that threonine started at colitis onset delayed recovery, while the same dose after inflammation was established did not.

  • Timing separation from levodopa and other amino acids: an hour between threonine and levodopa, and two hours between threonine and gram doses of glycine or branched-chain amino acids, avoids transporter competition and a blunted drug effect.

Therapeutic Protocol

  • Standard neurological protocol: the dose used in the controlled spasticity trials was 4.5–6 g daily of oral L-threonine for two to four weeks, given as divided doses; this remains the only human schedule tested against placebo (Lee & Patterson, 1993).

  • Nutritional repletion protocol: the competing approach treats threonine as a nutrient, not a drug: 1–2 g daily added to a plant-predominant diet, sized to close the gap to roughly 20 mg per kilogram of body weight.

  • Who developed each approach: the neurological schedule came from Growdon and Wurtman’s group at Massachusetts General Hospital and the Massachusetts Institute of Technology; the requirement-based schedule from the Pencharz and Courtney-Martin tracer programme at the Hospital for Sick Children, Toronto.

  • Time of day: no trial compared timing. The spasticity trials dosed across the day; where the goal is repletion, taking threonine with the lowest-protein meal makes the added amino acid least redundant.

  • Half-life: no elimination half-life has been published for L-threonine. Free amino acids leave plasma within hours, but fasting plasma threonine remained elevated after four weeks at 6 g daily, indicating pool expansion rather than rapid washout (Matsumoto et al., 2025).

  • Single versus split dosing: split. The controlled trials divided 4.5–6 g across two or three doses, and splitting limits both the osmotic load on the gut and the transient oxidation spike that follows a large single amino acid bolus.

  • Genetic variants that change the dose: protocols exclude carriers of two PCCA, PCCB or MUT variants entirely; single-copy carriers and people with B12-responsive methylmalonic aciduria are kept at the low end with methylmalonic acid monitoring.

  • Sex-based dosing: all dose-ranging and requirement data come from men. Where women are dosed, protocols scale by body weight rather than using the fixed gram figures from the trials, since the trial cohorts averaged roughly 65–75 kg.

  • Older adults: no requirement figure exists for people over 60; a tracer trial in that group is recruiting. Until it reports, protocols apply the young-adult figure with a wider margin and check vitamin B12 first.

  • Baseline biomarkers that guide the dose: fasting plasma threonine within an amino acid panel sets the starting point; a value in the lower part of the reference range with protein intake under 0.8 g per kilogram supports the higher end.

  • Pre-existing conditions that change the protocol: inflammatory bowel disease raises demand, so a requirement trial in Crohn’s disease is running; chronic kidney disease and cirrhosis lower the ceiling because the prescribed protein allowance, not the trial dose, governs.

Discontinuation & Cycling

  • Short-term rather than lifelong: every controlled trial ran two to four weeks, with a single one-year motor neuron disease trial; no study supports indefinite use, so protocols frame threonine as a time-limited trial with a defined endpoint.

  • Withdrawal effects: none reported. Threonine is a dietary constituent, not a receptor agonist, and no rebound spasticity, dependence or discontinuation syndrome appeared in the crossover trials, where participants moved between threonine and placebo periods.

  • Tapering: not applicable in the trials, which stopped threonine abruptly at the end of each two-week period without incident. Where it is used alongside an antispasticity drug, the drug rather than threonine sets any taper.

  • Cycling: no efficacy loss over time has been documented, so there is no established efficacy rationale for cycling. Some protocols cycle 8 weeks on and 4 weeks off purely to re-test whether the effect is still present.

Sourcing and Quality

  • Form: the free crystalline L-form is the only one used in human protein synthesis. DL-threonine and D-threonine are not utilised and appear only in older or non-food-grade material, so the label reading “L-threonine” is the first check.

  • Manufacturing route: essentially all commercial L-threonine is made by bacterial fermentation using engineered Escherichia coli or Corynebacterium glutamicum, then crystallised. Chemical synthesis gives racemic mixtures and is not used for food-grade material.

  • Grade and specification: food- or pharmaceutical-grade material carries a United States Pharmacopeia (USP) or Food Chemicals Codex monograph specification, typically 98.5% assay or higher with defined limits on residual solvents and heavy metals. Feed-grade threonine carries no such limits.

  • Third-party testing: an NSF Certified for Sport, Informed Choice or USP Verified mark confirms identity, assay and contaminant limits independently of the brand. A lot-specific certificate of analysis naming the assay method is the minimum substitute.

  • Reputable suppliers: Ajinomoto and Evonik dominate bulk fermentation and supply many finished-goods brands; among consumer brands, NOW Foods and BulkSupplements publish lot-level certificates for single amino acid powders. Upstream manufacturer identity matters more than the brand on the container.

  • Storage and stability: crystalline L-threonine is hygroscopic and cakes in humid air. Sealed opaque containers kept dry preserve assay; discoloured or clumped powder signals moisture ingress rather than degradation of the amino acid itself.

Practical Considerations

  • Time to effect: in the spasticity trials, tone changes were measured at the end of two-week periods, so two weeks is the shortest interval at which an effect has been demonstrated. Repletion of a dietary shortfall shows in plasma within days.

  • Common pitfalls: double-counting threonine already supplied by a protein powder; expecting a glycine-like sedative effect that human trials did not produce; and inferring human benefit from roundworm and piglet data.

  • Regulatory status: In the United States it is a dietary ingredient under the Dietary Supplement Health and Education Act (DSHEA); in the European Union it is a feed additive, cleared on European Food Safety Authority opinions prepared from manufacturer-submitted dossiers. No medicinal approval exists.

  • Cost and accessibility: bulk crystalline L-threonine is among the cheapest single amino acids, typically well under USD 0.50 per gram, and needs no prescription. Cost is not a barrier and does not distinguish it from its alternatives.

  • Payer incentives: L-threonine and its comparators for muscle stiffness, baclofen and tizanidine, are all inexpensive generics, so no institutional payer has a systematic financial reason to favour one over another. Botulinum toxin injection is far costlier, which cuts the other way.

  • Effect size expectations: the one benefit with controlled human support is small; the investigators who found it described it as real but not clinically valuable, which sets a realistic ceiling on what a trial of it can deliver.

Interaction with Foundational Habits

  • Sleep: Indirect and unproven. Threonine is often marketed as a glycine precursor for sleep, but the one trial that measured it found no rise in blood or spinal fluid glycine after oral dosing. No sleep endpoint has been tested; direct glycine at 3 g remains the studied option for that purpose.

  • Nutrition: Direct and substitutive. Threonine competes with the same food protein it is meant to supplement: 100 g of mixed dietary protein already supplies roughly 4 g. Cottage cheese, poultry, fish, eggs and lentils are dense sources; the supplement is redundant on a high-protein omnivorous pattern.

  • Exercise: Neutral, with no blunting or potentiating effect documented. Threonine is not a branched-chain amino acid and does not activate the mTOR pathway (a master switch for protein building) in the way leucine does, so it neither drives nor blunts a training response. Timing around workouts is untested.

  • Stress management: Indirect and speculative. The proposed link runs through glycine’s calming signalling, which human dosing did not raise; no trial has measured cortisol, perceived stress or heart rate variability with threonine.

Monitoring Protocol & Defining Success

Baseline testing before starting establishes both whether a shortfall exists and whether the disposal route is intact. A fasting plasma amino acid panel gives the threonine value in context; a liver panel with aspartate aminotransferase and alanine aminotransferase, plus creatine kinase, sets the reference against which the enzyme rise reported at 9 g daily would be read; and serum vitamin B12 with methylmalonic acid tests the propionate pathway that clears threonine. An estimated glomerular filtration rate is added where kidney function is uncertain.

Ongoing monitoring follows a simple cadence: the liver and muscle enzymes are repeated at 8 weeks after reaching the target dose, then at 6 months, then annually while the dose is stable. Plasma amino acids and methylmalonic acid are repeated at 6 months and annually thereafter.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Plasma threonine, fasting 120–180 µmol/L Confirms a shortfall exists before dosing Conventional reference range is wider, roughly 90–240 µmol/L; needs a 10–12 hour fast and is drawn within a full amino acid panel
Aspartate aminotransferase (AST) 15–25 U/L Detects the enzyme rise reported at 9 g daily AST = a liver and muscle enzyme. Conventional upper limit is about 40 U/L; pair with ALT and CK, and draw before strenuous exercise
Alanine aminotransferase (ALT) 10–25 U/L Separates liver from muscle as the source of an AST rise ALT = a mostly liver-specific enzyme. Conventional upper limit is about 55 U/L in men and 45 in women; fasting draw preferred
Creatine kinase (CK) 40–150 U/L Identifies muscle as the source of an enzyme rise CK = an enzyme released when muscle cells are stressed. Conventional upper limit is about 200 U/L in men and 170 in women; avoid drawing within 72 hours of hard resistance training, which raises it severalfold
Serum vitamin B12 500–900 pg/mL Confirms the propionate route that clears threonine is supported Conventional lower limit is 200 pg/mL, far below the functional target; interpret alongside methylmalonic acid, the more sensitive marker
Methylmalonic acid (MMA) Below 0.27 µmol/L Functional test of the propionate disposal pathway MMA = a compound that accumulates when the B12-dependent step is constrained. Conventional upper limit is about 0.40 µmol/L; rises before serum B12 falls; less distorted by a recent B12 dose
Estimated glomerular filtration rate (eGFR) Above 90 mL/min/1.73 m² Establishes whether a prescribed protein restriction governs the dose eGFR = a calculated measure of kidney filtering capacity. Conventionally 60 mL/min/1.73 m² and above is reported as normal; values below 30 place a person in the avoid list; creatinine-based estimates skew high with large muscle mass
High-sensitivity C-reactive protein Below 1.0 mg/L Flags the active inflammation during which threonine is deferred A general marker of body-wide inflammation. Conventional cardiovascular cut-off is 3.0 mg/L; a value above 10 usually signals acute illness rather than chronic inflammation
Fecal calprotectin Below 50 µg/g Detects an active bowel flare A stool marker of gut inflammation, relevant only where inflammatory bowel disease is present; conventional cut-off for active disease is 150–250 µg/g

Qualitative markers tracked alongside the labs:

  • Muscle tone and ease of movement: where stiffness is the target, a change is expected within two weeks, the interval at which the controlled trials measured it.
  • Digestive tolerance: nausea, bloating or loose stools appearing within days of a dose increase mark the practical ceiling.
  • Energy and exercise recovery: no trial has measured either; a change here more likely reflects total protein intake than threonine specifically.
  • Sleep quality: tracked because the glycine rationale predicts it, and because the absence of any change is itself informative given that human dosing did not raise glycine.

Emerging Research

  • Threonine requirement in adults over 60: A single-group tracer study at the Hospital for Sick Children is recruiting 40 healthy adults aged 60–90 across seven threonine intakes from 5 to 45 mg per kilogram daily (NCT06225648). It would be the first requirement figure for this age group.

  • Threonine requirement in Crohn’s disease: A parallel Hospital for Sick Children study is recruiting 10 adult men with Crohn’s disease to test whether intestinal inflammation raises the requirement, as animal work predicts (NCT04740541). A completed Nestlé-sponsored study of 86 adults addressed the same question (NCT02423460).

  • Amino acid fortification for environmental enteric dysfunction: Environmental enteric dysfunction (a leaky, inflamed gut lining common where sanitation is poor) is the target of a Malawi trial giving 66 stunted children a corn-soy porridge fortified with indispensable amino acids including threonine — the first human test of the gut-barrier hypothesis (NCT06617130).

  • Whether adding threonine or blocking it extends life: The two invertebrate findings point opposite ways: supplementation extended healthspan (Kim et al., 2022) while blocking threonine breakdown extended lifespan (Ravichandran et al., 2018). Resolving this in a mammal would settle whether supplementation is the right direction.

  • Threonine restriction as a cancer add-on: Work in glioblastoma showed that tumour stem cells accumulate threonine to sustain a transfer RNA modification, and that dietary threonine restriction slowed growth and improved chemotherapy response in mice (Wu et al., 2024). Human dietary trials have not begun.

  • Replication of the high-dose enzyme signal: The single dose-ranging safety trial found aspartate aminotransferase and creatine kinase rising at 9 g daily but not 12 g, an inconsistency it could not explain (Matsumoto et al., 2025). No replication is registered, and the trial enrolled men only.

Conclusion

L-threonine is a building block the body cannot make and must take in from food. Almost anyone eating adequate protein already takes in several times the amount needed, and that single fact frames everything else: for a well-fed person the supplement adds something that is not in short supply.

Where controlled human testing exists, it is narrow. Small trials in people whose muscles stay involuntarily tight after nerve damage found a real but slight easing of that tightness at gram-level doses, and the investigators themselves called the change too small to matter in daily life. Trials in a progressive nerve-wasting disease found nothing. The more ambitious claims, slower aging, a stronger gut lining, better sleep, rest on worms, piglets and poultry, and two of the most striking animal results point in opposite directions.

Safety looks reassuring within limits. A four-week dose-ranging study in healthy men found no harm up to twelve grams daily, alongside one unexplained enzyme signal at a lower dose. That study was funded by a company that manufactures the compound, which does not invalidate it but belongs on the record, as does the fact that it enrolled men only.

What stands up, then, is a cheap and well-tolerated amino acid with one small confirmed effect in a specific clinical setting, and a large gap between what is marketed and what has been measured.

Top - Benefits - Risks - Protocol